Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPhysiomics Regulatory News (PYC)

Share Price Information for Physiomics (PYC)

Share Price is delayed by 15 minutes
Get Live Data
0.60    0.00 (0.00%)
Bid:
0.55
Ask:
0.65
Spread: 0.10 (18.182%)
Market Cap: £2.72m
PYC Live PriceLast checked at - London Stock Exchange

Intraday Physiomics Share Chart

Director Dealing

12 Aug 2020 07:00

RNS Number : 8427V
Physiomics PLC
12 August 2020
 

12 August 2020

Physiomics plc

("Physiomics") or ("the Company")

 

Director Dealing

 

The Company announces that it received notice today that Dr Jim Millen sold 597,332 ordinary shares in the Company at 6.45p per share to cover the cost of his exercise of options announced on 5 August 2020.

 

Following the sale of shares, the total holdings of Dr Jim Millen will be 1,386,947, representing approximately 1.42 per cent. of the Company's issued share capital.

 

 

The information contained within this announcement is deemed by the Company to constitute inside information under the Market Abuse Regulation (EU) No. 596/2014.

 

 

Enquiries:

 

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

Richard Tulloch & James Dance

+44 (0)20 7409 3494

 

 

 

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

James Millen

2

Reason for the notification

a)

Position/status

Director, CEO

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Physiomics plc

b)

LEI

213800A71DSZ6ABMTQ91

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary shares

 

 

 

GB00BDR6W943

b)

Nature of the transaction

Disposal of shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

6.45p

597,332

d)

Aggregated information

- Aggregated volume

- Price

 

597,332

At 6.45p per share

e)

Date of the transaction

11-8-2020

f)

Place of the transaction

XLON, AIM

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHPBMRTMTJBBFM
Date   Source Headline
13th Dec 20217:00 amRNSMerck Contracts
23rd Nov 20213:30 pmRNSResult of AGM
12th Nov 202112:00 pmRNSConference presentation
12th Nov 202112:00 pmRNSConference presentation
27th Oct 20211:00 pmRNSPosting of Annual Report and AGM Notice
22nd Oct 20217:00 amRNSContract awards
30th Sep 20213:00 pmRNSResults Presentation and DoseMeRx Update
30th Sep 20217:00 amRNSFinal Results
16th Sep 20212:45 pmRNSPARNTER study recruits first patient
15th Sep 20217:00 amRNSNotice of Results and Investor Presentation
31st Aug 20217:00 amRNSPhysiomics hires Head of Business Development
19th Jul 20217:00 amRNSPhysiomics expands technical team
29th Jun 20219:16 amRNSDirector Dealing
21st May 20214:40 pmRNSDirector Dealing
21st May 20217:00 amRNSContract awards
14th May 20217:00 amRNSContract award
11th May 20217:00 amRNSContract award
10th May 20217:00 amRNSTrading update
9th Apr 20212:00 pmRNSConference presentation
22nd Mar 20217:00 amRNSDirector/PDMR Shareholding
12th Mar 20217:00 amRNSPresentation and Q&A on Company's Interim Results
4th Mar 20217:00 amRNSInterim Results Presentation
2nd Mar 202110:12 amRNSIssue of Options
1st Mar 20217:00 amRNSInterim Results
15th Feb 20217:00 amRNSValiRx Agreement
18th Dec 20207:00 amRNSHolding(s) in Company
17th Dec 20202:00 pmRNSPartnership with TRHC's DoseMeRx®
17th Dec 20207:00 amRNSMerck Contracts
14th Dec 20207:00 amRNSApproval of NIHR-funded PARTNER study
17th Nov 202012:59 pmRNSResult of AGM
22nd Oct 20208:30 amRNSPosting of Annual Report and AGM Notice
22nd Oct 20207:00 amRNSPosting of Annual Report and AGM Notice
16th Oct 20207:00 amRNSContract awards
6th Oct 20209:00 amRNSPresentation and Q&A on Company’s Final Results
30th Sep 20207:00 amRNSFinal Results and Notice of AGM
25th Sep 20207:00 amRNSFull year results release date and shareholder Q&A
11th Sep 20207:00 amRNSHolding(s) in Company
12th Aug 20207:00 amRNSDirector Dealing
5th Aug 20201:00 pmRNSIssue of Equity
5th Aug 20207:00 amRNSIssue of Equity and Director Dealing
4th Aug 20207:00 amRNSTrading update
31st Jul 20207:00 amRNSPhysiomics awarded contract by Astellas Pharma Inc
22nd Jul 202011:45 amRNSShare Price Movement
17th Jul 20209:00 amRNSPrice Monitoring Extension
6th Jul 202010:00 amRNSDirector dealing
30th Jun 20202:30 pmRNSContract award and update
22nd Jun 20207:00 amRNSConference presentation
10th Jun 20201:00 pmRNSHolding(s) in Company
27th May 20207:00 amRNSFundraise
15th May 20201:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.